button

 

EULAR2021

EULAR Congres 2021

Het EULAR Congres is jaarlijks de plek waar vijftienduizend reumatologen en andere zorgprofessionals elkaar ontmoeten en nieuwe kennis en behandelinzichten delen. Maar dit jaar wordt het EULAR Congres wederom virtueel gehouden en wel van woensdag 2 tot zaterdag 5 juni. Ook Pfizer is dit jaar op het congres te vinden. We ondersteunen diverse symposia en meet de experts-sessies over RA, PsA en axSpA. Een selectie van abstracts over Xeljanz bij geregistreerde indicaties vind u hier. We zien u graag op de genoemde bijeenkomsten. Mocht u niet in de gelegenheid zijn om ze ‘live’ bij te wonen, neem dan een kijkje op de EULAR on-demand site waar u later opnames van de bijeenkomsten kunt vinden.

Rheumatoid Arthritis & Psoriatic Arthritis

 2 Symposia and 2 Meet-the-Expert sessions in which we seek to:

  • Determine the place of JAK inhibitors in the treatment paradigm 
  • Examine how to improve outcomes for our patients through better communication and goal setting 
  • Evaluate the totality of the data available that inform benefit risk discussions, when considering a JAK inhibitor. 
Wednesday 2 June, 3.45 pm to 4.15 pm.
Meet-the-Expert session:
‘Minding the Gap: Can Better Communication Improve Patiënt Outcomes?’ 
 
Wednesday 2 June, 6.15 pm to 7.15 pm.
Symposium:
‘JAK Inhibitors in RA, What, Where, How, Why, Who and en When?’  
 
Program Speaker
Introduction Gerd Burmester, Chair (Germany)
The Rationale for Selecting JAK Inhibitors as a Treatment Option in RA Elizabeth Perkins (United States)
What Have We Learned About JAK Inhibitors in RA? Hendrik Schulze-Koops (Germany)
Where Do JAK Inhibitors Fit Into the RA Treatment Paradigm? Ai Lyn Tak (United Kingdom)
Discussion and Q&A All faculty
Summary and conclusion Gerd Burmester, Chair (Germany)
 
 
Thursday 3 June, 3:00 pm to 3:30 pm.
Meet-the-Expert session:
‘Personalising Patiënt Care: Reflections on the Place of JAK Inhibitors in Rheumatology’ 
 
Friday 4 June, 5.30 pm to 7.00 pm.
Symposium
‘Exploring Advanced Therapeutic options in PsA: A Domain-Driven Approach’  
 
Program Speaker
Introduction Laura Coates, Chair (United Kingdom)
A Domain-Driven Approach to Advanced  Treatment Selection in PsA Consideration of  Patient Characteristics Frank Behrens (Germany)
When Evaluating Advanced Treatment Selection  in PsA Lihi Eder (Canada)
The Role of Patient Preference in the Selection of  Advanced PsA Treatment Diamant Thaçi (Germany)
Discussion and Q&A All faculty
Summary and conclusion Laura Coates, Chair (United Kingdom)

 

Selectie van abstracts over Xeljanz bij geregistreerde indicaties

Voor de behandeling van RA en PsA met Xeljanz zijn de volgende abstracts geaccepteerd. Pas na opheffen van het embargo is doorklik mogelijk.

Bekijk de RA abstracts

Bekijk de PsA abstracts

Axial Spondyloarthritis

Featuring top experts in the field, this symposium will provide:

  • An overview of how the immunopathogenesis of axial spondyloarthritis (axSpA) can be targeted to ameliorate the manifestations of disease
  • A discussion of unmet needs and treatment goals in axSpA as they relate to diagnosis and disease management, respectively
  • Insights on how existing and emerging advanced therapies in axSpA, and specifically in ankylosing spondylitis (AS), may address current gaps in disease management
Thursday 3 June, 8.15 am to 9.45 am.
Symposium 
‘Targeting the Immunopathogenesis of Axial Spondyloarthritis: Emerging Treatment Options’ 
 
Program Speaker
Introduction Denis Poddubnyy, Chair (Germany)
Targeting the Immunopathogenesis of axSpA Christopher Ritchlin (United States)
Treatment Goals in axSpA and Unmet Needs    of Patients and Physicians Victoria Navarro-Compán (Spain)
The Role of Advanced Therapies in Addressing  Unmet Needs in AS Irene van der Horst-Bruinsma (Netherlands)
Discussion and Q&A All falucity
Summary and conclusion

Denis Poddubnyy, Chair (Germany)

 

 

PP-XEL-NLD-1212